Merck KGaA, Darmstadt, Germany Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor
Retrieved on:
Wednesday, September 21, 2022
Biotechnology, Pharmaceutical, Oncology, Health, Data Management, Technology, Genetics, Clinical Trials, Aircraft Research and Development Unit RAAF, Merck Group, Electronics, Breast, Gene editing, NMS, TMZ, Neoplasm, Prostate, Health, GBM, Merck Millipore, Achievement, ADP, PARP1, Patient, Merck Serono, Entrepreneurship, Intelligence, Exercise, PARP, Science, DNA repair, Research, DNA, Health care, BRCA, Merck, Temozolomide, Complex conjugate, Pharmaceutical industry, Medical imaging, Glioblastoma, Oncology
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l.
Key Points:
- Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l.
- (NMS) for the next-generation highly selective and brain-penetrant PARP1 (poly (ADP-ribose) polymerase) inhibitor, NMS-293.
- Under the current agreement, Merck KGaA, Darmstadt, Germany will make early payments (up-front and option exercise fees) of up to $65 million to NMS.
- Upon exercise of the option, NMS will grant to Merck KGaA, Darmstadt, Germany the exclusive rights to research, develop, manufacture, and commercialize NMS-293.